MBMarion Berge

Marion Berge

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Marion Berge has a total of 33 co-authors. Here are the top co-authors by number of shared publications:

  • Eric Caudron

    Pharmacy Department, Georges Pompidou European Hospital, AP-HP, Paris, France

    2 shared publications
  • A. Puszkiel

    Department of Pharmacokinetics and Pharmacochemistry, Cochin University Hospital, Assistance Publique–Hôpitaux de Paris, CARPEM, Paris, France

    1 shared publication
  • A. Thomas-Schoemann

    Department of Clinical Pharmacy, Cochin University Hospital, Assistance Publique–Hôpitaux de Paris, CARPEM, Paris, France

    1 shared publication
  • Alexandre Karras

    AP-HP, Nephrology Department, European Georges Pompidou Hospital, Paris, France

    1 shared publication
  • Ali Tfayli

    Lipides: systèmes analytiques et biologiques, Université Paris-Saclay, Châtenay-Malabry, France

    1 shared publication
  • Antoine Dowek

    Clinical Pharmacy Department, Gustave Roussy Cancer Campus, 94800 Villejuif, France; Université Paris-Saclay, Lipides : systèmes analytiques et biologiques, 91400 Orsay, France

    1 shared publication

Latest Publications

  • Open Access

    Rapid quantification and classification of five vinca alkaloids used in cancer therapy by flow injection analysis with UV detection and chemometrics

    by Eric Caudron, Cécile Boughanem, Marion Berge, Jehanne Saidi, Antoine Dowek, Laetitia Minh Mai Lê

    UV-visible spectroscopy with chemometrics enables accurate vinca alkaloid discrimination, while Bland–Altman analysis compares HPLC and FIA. Real-world data validate findings, ensuring robust control of anticancer drugs for precise patient dosing.


  • Open Access

    Flow Injection Analysis With UV Detection Versus Raman Spectroscopy for the Quantitative Analysis of Remdesivir

    by Marion Berge, Jonhatan Siboni, Carole Mequinion, Eric Caudron, Laetitia Lê

    The quality and the security of preparations in hospital centres are essential to guarantee the patient's safety. The development of fast and efficient analytical methods is required to control the finished product before use. In this context, the study aimed to compare the performance and interchangeability of two spectral analytical methods: the flow injection analysis (FIA) with UV detection and the Raman spectroscopy for the quality control of preparation before use to quantify the remdesivir as a SARS‐CoV‐2 drug. A quantitative study of remdesivir was performed using clinically relevant concentration solutions ranging from 0.25 to 1.625 mg.mL−1 in 0.9% NaCl. Samples were analysed by FIA‐UV at 245 nm and by a handheld Raman spectroscopy at 785 nm. Quantitative models were developed using a calibration set (n = 45 samples) and optimized using a validation set (n = 27). An external validation test set (n = 58) was used to compare the two methods by a Bland–Altman plot. Partial least square regression was used to analyse Raman spectra, while univariate analysis was performed at 245 nm for FIA‐UV. The regression coefficient was higher than 0.990 for both methods, and the root mean square error of prediction was 0.031 mg.mL−1 for Raman spectroscopy. The Bland–Altman plot confirmed the interchangeability of the two methods and the potential of Raman spectroscopy to control remdesivir during clinical preparation in the hospital.


  • Pharmacokinetic drug–drug interaction between olaparib and apixaban: a case report

    by M. Berge, J. S. Giraud, S. De Percin, A. Puszkiel, A. Thomas-Schoemann, B. Blanchet


  • Open Access

    Effectiveness of a ‘do not interrupt’ vest intervention to reduce medication errors during medication administration: a multicenter cluster randomized controlled trial

    by Sarah Berdot, Aurélie Vilfaillot, Yvonnick Bezie, Germain Perrin, Marion Berge, Jennifer Corny, Thuy Tan Phan Thi, Mathieu Depoisson, Claudine Guihaire, Nathalie Valin, et al.

    Background: The use of a ‘do not interrupt’ vest during medication administration rounds is recommended but there have been no controlled randomized studies to evaluate its impact on reducing administration errors. We aimed to evaluate the impact of wearing such a vest on reducing such errors. The secondary objectives were to evaluate the types and potential clinical impact of errors, the association between errors and several risk factors (such as interruptions), and nurses’ experiences. Methods: This was a multicenter, cluster, controlled, randomized study (March–July 2017) in 29 adult units (4 hospitals). Data were collected by direct observation by trained observers. All nurses from selected units were informed. A ‘Do not interrupt’ vest was implemented in all units of the experimental group. A poster was placed at the entrance of these units to inform patients and relatives. The main outcome was the administration error rate (number of Opportunities for Error (OE), calculated as one or more errors divided by the Total Opportunities for Error (TOE) and multiplied by 100). Results: We enrolled 178 nurses and 1346 patients during 383 medication rounds in 14 units in the experimental group and 15 units in the control group. During the intervention period, the administration error rates were 7.09% (188 OE with at least one error/2653 TOE) for the experimental group and 6.23% (210 OE with at least one error/3373 TOE) for the control group (p = 0.192). Identified risk factors (patient age, nurses’ experience, nurses’ workload, unit exposition, and interruption) were not associated with the error rate. The main error type observed for both groups was wrong dosage-form. Most errors had no clinical impact for the patient and the interruption rates were 15.04% for the experimental group and 20.75% for the control group. Conclusions: The intervention vest had no impact on medication administration error or interruption rates. Further studies need to be performed taking into consideration the limitations of our study and other risk factors associated with other interventions, such as nurse’s training and/or a barcode system. Trial registration: The PERMIS study protocol (V2–1, 11/04/2017) was approved by institutional review boards and ethics committees (CPP Ile de France number 2016-A00211–50, CNIL 21/03/2017, CCTIRS 11/04/2016). It is registered at ClinicalTrials.gov (registration number: NCT03062852, date of first registration: 23/02/2017).


  • Rapid discrimination and quantification analysis of five antineoplastic drugs in aqueous solutions using Raman spectroscopy

    by Laetitia Minh Mai Lê, Marion Berge, Ali Tfayli, Jiangyan Zhou, Patrice Prognon, Arlette Baillet-Guffroy, Eric Caudron